A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea

Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea. Therefore this trial will help evaluate the lipid lowering effect of Vytorin® in asian population with metabolic syndrome.

Inclusion Criteria:

• Diagnosis of the metabolic syndrome according to 2005 American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) scientific statement
• No history of diabetes and 100 <=LDL-C <=250 mg/dl

Exclusion Criteria:

• Myocardial Infarction, coronary artery bypass surgery, or angioplasty within 3 months
• Congestive heart failure defined by New York Heart Association (NYHA) class III or IV
• Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
• Uncontrolled hypertension
• Unstable angina